Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention
Study Details
Study Description
Brief Summary
Giving oral Cabergoline or calcium infusion in women at high risk for developing ovarian hyperstimulation syndrome in context of assisted reproductive technologies aiming in its prevention
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 3 |
Detailed Description
Women undergoing in vitro fertilization or intracytoplasmic sperm injection whom were at high risk for developing ovarian hyperstimuation syndrome were received either oral Cabergoline.5mg tablets for 7days starting on ovum pick up day and continued for 7days or received 10ml of 10%calcium gluconate in 200ml normal saline on ovum pick up day and continued for 4days
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Active Comparator: Calcium infusion 10ml 10%calcium gluconate in 200ml normal saline solution given intravenously over thirty minutes, on ovum pick up day and continued for 4days |
Drug: Calcium Gluconate
Giving 10 ml of 10 % calcium gluconate on 200 ml normal saline solution o.9% intravenously over thirty minutes starting on ovum pick up day and continued for four days
Other Names:
|
Active Comparator: Oral Cabergoline Receiving oral Cabergoline (cabergamon 0.5 milligram tablet ) from ovum pick up day and continued for 7days,once daily |
Drug: Oral Cabergoline
Giving oral Cabergoline tablet 0.5 milligram daily starting on ovum pick up day and continued for seven days
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Occurrence of ovarian hyperstimuation syndrome [20 days from ovum pick up day]
Clinical condition occurred in context of assisted reproductive technologies in which there serous sacs fluid accumulation and hemoconcentration
Secondary Outcome Measures
- Types of ovarian hyperstimuation syndrome and severity [20 days from ovum pick up day]
Clinical severity either mild ,moderate or severe and its type either early or late onst
- Chemical pregnancy [14 day from embryos transfer day]
Positive human chorionic Gonadotropin in blood
- Clinical pregnancy [5 week from embryos transfer day]
Intrauterine gestational sac
Eligibility Criteria
Criteria
Inclusion Criteria:
- women undergoing assisted reproductive technologies whom at high risk for developing ovarian hyperstimulation syndrome as with high basal antimullerian hormone ,excess antral follicular count ,high seum estradiol on day of humian choronic gonadotrophin
Exclusion Criteria:women with other endocrinopathy as congenital adrenal hyperplasia , hyperprolactinemia,diabetes
-
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Ashraf nassif Elmantwe | Cairo | Elqalopia | Egypt | 5131 |
Sponsors and Collaborators
- Benha University
Investigators
- Principal Investigator: Ashraf N Elmantwe, MD, Benha University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Ashraf Elmantwe 1